LabAutomation 2006 - SLAS
LabAutomation 2006 - SLAS
LabAutomation 2006 - SLAS
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
MP71<br />
Sang Jun Son<br />
University of Maryland<br />
Silver Spring, Maryland<br />
triaza@gmail.com<br />
Sang Bok Lee, University of Maryland<br />
<strong>LabAutomation</strong><strong>2006</strong><br />
Magnetic Nanotubes for Magnetic-Field-Assisted Bioseparation, Biointeraction, and<br />
Drug Delivery<br />
Tubular structure of nanoparticle is highly attractive due to their structural attributes, such as the distinctive inner and outer surfaces, over<br />
conventional spherical nanoparticles. Inner voids can be used for capturing, concentrating, and releasing species ranging in size from large<br />
proteins to small molecules. Distinctive outer surfaces can be differentially functionalized with environment-friendly and/or probe molecules<br />
to specific target. Magnetic particles have been extensively studied in the field of biomedical and biotechnological applications, including<br />
drug delivery, biosensors, chemical and biochemical separation and concentration of trace amount of specific targets, and contrast<br />
enhancement in magnetic resonance imaging (MRI). Therefore, by combining the attractive tubular structure with magnetic property, the<br />
magnetic nanotube can be an ideal candidate for the multifunctional nanomaterial toward biomedical applications, such as targeting<br />
drug delivery with MRI capability. Here, we successfully synthesized magnetic silica-iron oxide composite nanotubes and demonstrated<br />
magnetic-field-assisted chemical and biochemical separations, immunobinding, and drug delivery.<br />
MP72<br />
Joe Olechno<br />
Labcyte<br />
Sunnyvale, California<br />
joe.olechno@labcyte.com<br />
Co-Author(s)<br />
Jean Shieh<br />
A. Mark Bramwell<br />
Richard Ellson<br />
Improving IC50 Analyses by Reducing Compound Waste, Compound Precipitation,<br />
Accumulated Error and Consumables Cost<br />
IC50 analyses are typically time- and labor-intensive, requiring multiple dilution steps and significant amounts of sample compound. Often,<br />
in order to obtain concentrations of chemical compound suitable for the assay, stock solutions of high concentration are used. These are<br />
diluted via an aqueous intermediate to reduce final DMSO concentration. This frequently results in sample precipitation and the generation<br />
of inaccurate data. Standard processes use multiple serial dilutions which result in significant accumulated error. Some compounds may<br />
adhere to pipette tips, reducing the actual concentration and increasing the possibility of contaminating other dilutions via carry-over.<br />
Typically, higher DMSO levels in the final assay negatively affect the assay, especially in the case of cell-based assays.<br />
A system incorporating acoustic ejection of nanoliter droplets of active compounds dissolved in DMSO improves IC50 analyses by<br />
eliminating multiple serial dilutions and thus, accumulated error (CV%
Change language